The training of staff on the ITAC (Inpatient Treatment with Anti-Coronavirus Immunoglobulin) study took place in the month of September, 2020. ITAC is a clinical trial which commences in October 2020. This study will evaluate the potential impact of hyperimmunglobulin as a treatment option in #COVID19 infected patients, who present mild to moderate symptoms.

The Nigerian Principal Investigator has this to say: “We are training the participants to be able to implement the ITAC study procedures for the Nigerian sites.” – Dr. Eriobu Nnakelu, Evaluation Manager IRCE, Principal Investigator START and D2EFF study